Use of a cd28 binding substance for making a pharmaceutical composition

Abstract

The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells.

1 - 10 . (canceled) 
     
     
         11 . A method for the treatment or prophylaxis of Guillain-Barré syndrome or chronic demyelinating polyneuropathy, wherein either
 a pharmaceutical composition is administered to a patient, comprising a CD28-specific superagonistic monoclonal antibody or a mimicry compound hereto and in a galenic preparation for a defined and suitable form of administration comprising intraveneous injection; or 
 a body liquid is taken from a patient, comprising blood comprising T lymphocytes or precursor cells hereto, and the body liquid, possibly after a processing step, is reacted with a CD28-specific superagonistic monoclonal antibody (mAb) or a mimicry compound hereto, and the thus treated body liquid is again administered to the patient. 
 
     
     
         12 . The method of  claim 11 , wherein the mAb is produced from a non-human mammal immunized with CD28 or a partial sequence thereof. 
     
     
         13 . The method of  claim 11 , wherein the mimicry compound is obtainable by a screening method, in which a prospective mimicry compound or a mixture of prospective mimicry compounds is subjected to a binding assay with CD28 or a partial sequence thereof, wherein the CD28 partial sequence comprises a C′D loop, and substances binding to CD28 or to the partial sequence therefore are selected, followed by an assay for testing for superagonistic stimulation of several to all sub-groups of T lymphocytes. 
     
     
         14 . The method of  claim 11 , wherein the mAb is obtainable from hybridoma cells, as filed under the DSM numbers DSM ACC2531 (mAb: 9D7 or 9D7G3 H 11) or DSM ACC25 3 0 (mAb: 5.11A or 5.11AIC2H3). 
     
     
         15 . The method of  claim 11 , wherein the mAb or the mimicry compound comprises one or more of the sequences Seq. ID 9, 11, 13 or 15, or one or more of the sequences Seq. ID 10, 12, 14, 16 or one or more of the sequences 18 or 19, or sequences being homologous thereto. 
     
     
         16 . The method of  claim 12 , wherein the CD28 partial sequence comprises a CD loop, wherein cells are taken from the non-human mammal, hybridoma cells are produced from the cells, and the thus obtained hybridoma cells are selected such that in their culture supernatant there are mAbs that superagonistically bind to CD28. 
     
     
         17 . The method of  claim 11 , wherein the body liquid is administered to the patient by intraveneous injection.